Clinical trial
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced…
NCT00002560 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002560 |
|---|---|
| Title | Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma |
| Official title | PHASE II TRIAL OF MONOCLONAL ANTIBODY 3F8 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) FOR NEUROBLASTOMA |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Biological |
| Interventions | monoclonal antibody 3F8, sargramostim |
| Enrollment | 40 |
| Start date | Feb 1, 1994 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: